Other
BioNTech (BNTX / 22UA GY) has advanced a Phase 3 trial of pumitamig with Gilead (GILD)
StockNow breaking-news AI analysis
BioNTech plans, subject to regulatory approval, to replace chemotherapy in ROSETTA Breast-01 with Gilead’s sacituzumab govitecan; the combination remains investigational.
Related stocks
2 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.